Document Detail


Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population.
MedLine Citation:
PMID:  20935029     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Anti-aquaporin-4 antibodies are believed to have a central pathogenetic role in neuromyelitis optica (NMO). B-cell activating factor (BAFF) is one of the crucial factors that determines the fate and survival of B cells and may play a role in induction of antibody-mediated autoimmunity.
OBJECTIVES: To evaluate the blood and cerebrospinal fluid (CSF) levels of BAFF in NMO and multiple sclerosis (MS) patients.
METHODS: Peripheral blood samples were collected from 21 definite NMO patients, 22 healthy controls and 45 MS patients and CSF from 8 NMO and 11 MS patients. BAFF levels were measured using an ELISA technique.
RESULTS: We found significantly higher levels of BAFF in the CSF of NMO patients compared with that in MS (215.6 ± 41 pg/ml in NMO and 77.4 ± 11 pg/ml in MS, p < 0.001). There were no differences in serum BAFF levels between NMO, MS and healthy donors. MS patients treated with interferon-beta (IFNβ) or glatiramer acetate (GA) had significantly higher serum BAFF levels, as compared with untreated patients (1227 ± 203 pg/ml in untreated MS, 2253 ± 83.4 pg/ml in GA-treated, p < 0.01, and 2106 ± 277.9 pg/ml in interferon-treated, p < 0.05)
CONCLUSION: The presence of increased BAFF, a soluble factor associated with B-cell activation in the proximity of the disease target organ (CSF) in NMO, and its increase in association with immunomodulating treatments, may help our understanding of the immunopathogenetic mechanisms involved in this disease and contribute to more successful and targeted therapeutic intervention.
Authors:
Adi Vaknin-Dembinsky; Livnat Brill; Naama Orpaz; Oded Abramsky; Dimitrios Karussis
Related Documents :
1365039 - Muscle morphometry in amyotrophic lateral sclerosis.
15124759 - Influence of ccr5 delta32 polymorphism on multiple sclerosis susceptibility and disease...
266529 - Oral radiographic changes in patients with progressive systemic sclerosis (scleroderma).
16618349 - Proton magnetic resonance spectroscopy of normal appearing white matter in asymptomatic...
20498549 - Differential changes in deep and cortical gray matters of patients with multiple sclero...
14745209 - Thalamic stimulation in patients with multiple sclerosis: long-term follow-up.
20730459 - Panniculitis: another clinical expression of gout.
15605329 - Acute flaccid paralysis associated with west nile virus: motor and functional improveme...
2607319 - Gastric ulcer is accompanied by a decrease of epidermal growth factor in gastric juice ...
Publication Detail:
Type:  Journal Article     Date:  2010-10-08
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  16     ISSN:  1477-0970     ISO Abbreviation:  Mult. Scler.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-12-01     Completed Date:  2011-03-21     Revised Date:  2011-10-04    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  England    
Other Details:
Languages:  eng     Pagination:  1453-7     Citation Subset:  IM    
Affiliation:
Department of Neurology and Laboratory of Neuroimmunology and the Agnes-Ginges Center for Neurogenetics, Hadassah-Hebrew University Hospital, Ein-Karem, Jerusalem, Israel. adembinsky@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
B-Cell Activating Factor / blood,  cerebrospinal fluid*
Enzyme-Linked Immunosorbent Assay
European Continental Ancestry Group
Female
Humans
Immunologic Factors / therapeutic use
Interferon-beta / therapeutic use
Male
Multiple Sclerosis / blood,  cerebrospinal fluid,  drug therapy
Neuromyelitis Optica / blood,  cerebrospinal fluid*
Peptides / therapeutic use
Chemical
Reg. No./Substance:
0/B-Cell Activating Factor; 0/Immunologic Factors; 0/Peptides; 0/TNFSF13B protein, human; 0/copolymer 1; 77238-31-4/Interferon-beta
Comments/Corrections
Comment In:
Mult Scler. 2011 May;17(5):639-40; author reply 641   [PMID:  21382861 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increasing incidence of multiple sclerosis in women in Northern Finland.
Next Document:  Interferon-{beta} is a key regulator of proinflammatory events in experimental autoimmune encephalom...